文献速递炎症性肠病

炎症性肠病中肿瘤坏死因子抑制剂与免疫介导炎症性疾病风险

Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-07-11

在丹麦(2005-2018)和法国(2008-2018)的两项全国性队列研究中,抗TNF治疗与类风湿关节炎、银屑病和化脓性汗腺炎风险升高相关,丹麦队列HR为1.66,法国队列HR为1.78,合并HR为1.76。与硫唑嘌呤相比,抗TNF治疗也显示风险升高,合并HR为2.94。

要点

  • 抗TNF治疗与类风湿关节炎、银屑病和化脓性汗腺炎风险升高相关,合并HR为1.76。
  • 与硫唑嘌呤相比,抗TNF治疗的风险更高,合并HR为2.94。

核心结论

  • 在两项全国性IBD患者队列中,抗TNF治疗与类风湿关节炎、银屑病和化脓性汗腺炎风险升高相关。

研究设计与样本

  • 在丹麦(2005-2018)和法国(2008-2018)开展的两项全国性队列研究,纳入所有IBD患者,丹麦队列18,258例,法国队列88,786例,总随访516,055人年。

主要发现

  • 抗TNF与类风湿关节炎、银屑病和化脓性汗腺炎风险升高相关:丹麦队列HR 1.66(95%CI 1.34-2.07),法国队列HR 1.78(95%CI 1.63-1.94),合并HR 1.76(95%CI 1.63-1.91)。
  • 与硫唑嘌呤相比,抗TNF与结局风险升高相关,合并HR 2.94(95%CI 2.33-3.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tumor necrosis factor inhibitors (anti-TNF) are effective therapies for several immune-mediated inflammatory diseases (IMIDs). However, case reports have identified the paradoxical occurrence of IMIDs in patients treated with anti-TNF. We studied the risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa after the initiation of anti-TNF therapy for inflammatory bowel disease (IBD). METHODS: We conducted 2 nationwide cohort studies comprising all patients with IBD in Denmark (2005-2018) and France (2008-2018). We obtained individual-level information on exposure to anti-TNF, diagnoses of IMIDs including rheumatoid arthritis, psoriasis, and hidradenitis suppurativa, and potential confounders from healthcare registers in the respective countries. We used Cox models to estimate hazard ratios (HRs) for the association between anti-TNF exposure and IMIDs and then pooled the estimates from the 2 cohorts. To test the robustness of our results, we performed an active comparator analysis of anti-TNF monotherapy vs azathioprine monotherapy. RESULTS: The Danish and French cohorts comprised 18,258 and 88,786 subjects with IBD, respectively, contributing a total of 516,055 person-years of follow-up. Anti-TNF was associated with an increased risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa in both the Danish (HR, 1.66; 95% confidence interval [CI], 1.34-2.07) and the French cohort (HR, 1.78; 95% CI, 1.63-1.94), with a pooled HR of 1.76 (95% CI, 1.63-1.91). Anti-TNF was also associated with an increased risk of the outcomes when compared with azathioprine (pooled HR, 2.94; 95% CI, 2.33-3.70). CONCLUSIONS: In 2 nationwide cohorts of IBD patients, anti-TNF therapy was associated with an increased risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ward D, Nyboe Andersen N, Gørtz S, et al. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases. Clin Gastroenterol Hepatol. 2023. PMID: 37442315. doi:10.1016/j.cgh.2023.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。